Prognoses of advanced esophago‑gastric junction cancer may be modified by thoracotomy and splenectomy

Hosoda,Kei; Yamashita,Keishi; Tsuruta,Harukazu; Moriya,Hiromitsu; Mieno,Hiroaki; Ema,Akira; Washio,Marie; Watanabe,Masahiko

doi:10.3892/ol.2017.7441

Prognoses of advanced esophago‑gastric junction cancer may be modified by thoracotomy and splenectomy

Authors:
- Kei Hosoda
- Keishi Yamashita
- Harukazu Tsuruta
- Hiromitsu Moriya
- Hiroaki Mieno
- Akira Ema
- Marie Washio
- Masahiko Watanabe
View Affiliations

Affiliations: Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252‑0374, Japan, Department of Medical Informatics, Kitasato University School of Allied Health Sciences, Sagamihara, Kanagawa 252‑0374, Japan
Published online on: November 17, 2017 https://doi.org/10.3892/ol.2017.7441
Pages: 1200-1210

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Globally, the incidence of esophago‑gastric junction (EGJ) cancer is rapidly increasing. However, the proposed strategies for the treatment of these types of cancer are so diverse that there is no established consensus on the optimal treatment. The aim of the present study was to identify independent prognostic factors to delineate the optimal strategies for the treatment of EGJ cancer. The medical records of 150 patients with EGJ cancer who underwent curative surgery at the Kitasato University were retrospectively reviewed. The median follow‑up period was 48 months. The patients with tumors that were classified as post‑treatment primary tumor stage 3 [(y)pT3] or higher had a 5‑year disease‑specific survival (DSS) rate of 53%, whereas those with tumors that were classified as (y)pT0‑2 had a 5‑year DSS rate of 90%. Therefore, prognostic analysis was restricted to those tumors that were designated (y)pT3 or higher. A multivariate Cox's proportional hazards model identified the following independent prognostic factors that negatively influenced the DSS: i) Presence of tumors classified as post‑treatment regional lymph node stage 1‑3 [(y)pN1‑3] [hazard ratio (HR), 3.62; 95% confidence interval (CI), 1.39‑12.36]; ii) not undergoing treatment with splenectomy (HR, 2.40; 95% CI, 1.15‑5.15); and iii) undergoing treatment with thoracotomy (HR, 2.07; 95% CI, 1.02‑4.23). In patients with (y)pN0 tumors, the DSS rate was significantly improved for those who underwent splenectomy than for those who did not (P=0.024). In patients with (y)pN1‑3 tumors, the DSS rate was significantly worse for those who underwent thoracotomy compared with those who did not (P=0.004). Splenectomy and thoracotomy may critically affect prognosis in locally advanced EGJ cancer that are classified as (y)pN0 and (y)pN1‑3, respectively. Surgical treatments require optimization in order to improve prognoses in advanced EGJ cancer.

View Figures

View References

1	Devesa SS, Blot WJ and Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 83:2049–2053. 1998. View Article : Google Scholar : PubMed/NCBI
2	Pohl H and Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 97:142–146. 2005. View Article : Google Scholar : PubMed/NCBI
3	Kusano C, Gotoda T, Khor CJ, Katai H, Kato H, Taniguchi H and Shimoda T: Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 23:1662–1665. 2008. View Article : Google Scholar : PubMed/NCBI
4	Blaser MJ and Saito D: Trends in reported adenocarcinomas of the oesophagus and gastric cardia in Japan. Eur J Gastroenterol Hepatol. 14:107–113. 2002. View Article : Google Scholar : PubMed/NCBI
5	Yamashita K, Sakuramoto S, Nemoto M, Shibata T, Mieno H, Katada N, Kikuchi S and Watanabe M: Trend in gastric cancer: 35 years of surgical experience in Japan. World J Gastroenterol. 17:3390–3397. 2011. View Article : Google Scholar : PubMed/NCBI
6	Rüdiger Siewert J, Feith M, Werner M and Stein HJ: Adenocarcinoma of the esophagogastric junction: Results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 232:353–361. 2000. View Article : Google Scholar : PubMed/NCBI
7	Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG and Brennan MF: Adenocarcinoma of the gastroesophageal junction: Influence of esophageal resection margin and operative approach on outcome. Ann Surg. 246:1–8. 2007. View Article : Google Scholar : PubMed/NCBI
8	Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, Nashimoto A and Hiratsuka M; Japan Clinical Oncology Group (JCOG9502), : Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: A randomised controlled trial. Lancet Oncol. 7:644–651. 2006. View Article : Google Scholar : PubMed/NCBI
9	van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
10	Zanoni A, Verlato G, Giacopuzzi S, Weindelmayer J, Casella F, Pasini F, Zhao E and de Manzoni G: Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center. Ann Surg Oncol. 20:1993–1999. 2013. View Article : Google Scholar : PubMed/NCBI
11	Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D and Mayer R: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092. 2008. View Article : Google Scholar : PubMed/NCBI
12	Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, et al: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol. 21:4592–4596. 2003. View Article : Google Scholar : PubMed/NCBI
13	Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, et al: A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sobin LH and Wittekind C: TNM Classification of Malignant Tumours. 7th. Wiley-Blackwell; New York, NY: 2009
15	Weitz J, D'Angelica M, Gonen M, Klimstra D, Coit DG, Brennan MF and Karpeh MS: Interaction of splenectomy and perioperative blood transfusions on prognosis of patients with proximal gastric and gastroesophageal junction cancer. J Clin Oncol. 21:4597–4603. 2003. View Article : Google Scholar : PubMed/NCBI
16	Dindo D, Demartines N and Clavien PA: Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 240:205–213. 2004. View Article : Google Scholar : PubMed/NCBI
17	Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, et al: The Clavien-Dindo classification of surgical complications: Five-year experience. Ann Surg. 250:187–196. 2009. View Article : Google Scholar : PubMed/NCBI
18	Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, Nishimura K, Takagi S, Azuma M, Ae T, Ishido K, et al: A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol. 69:407–413. 2012. View Article : Google Scholar : PubMed/NCBI
19	Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
20	Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
21	Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:457–481. 1958. View Article : Google Scholar
23	Ng CS, Wan IY and Yim AP: Impact of video-assisted thoracoscopic major lung resection on immune function. Asian Cardiovasc Thorac Ann. 17:426–432. 2009. View Article : Google Scholar : PubMed/NCBI
24	Hirai T, Matsumoto H, Yamashita K, Urakami A, Iki K, Yamamura M and Tsunoda T: Surgical oncotaxis-excessive surgical stress and postoperative complications contribute to enhancing tumor metastasis, resulting in a poor prognosis for cancer patients. Ann Thorac Cardiovasc Surg. 11:4–6. 2005.PubMed/NCBI
25	Goto H, Tokunaga M, Sugisawa N, Tanizawa Y, Bando E, Kawamura T, Niihara M, Tsubosa Y and Terashima M: Value of splenectomy in patients with Siewert type II adenocarcinoma of the esophagogastric junction. Gastric Cancer. 16:590–595. 2013. View Article : Google Scholar : PubMed/NCBI
26	Huang CM, Wang JB, Lu HS, Zheng CH, Li P, Xie JW and Zhang XF: Prognostic impact of splenectomy on advanced proximal gastric cancer with No. 10 lymph node metastasis. Chin Med J (Engl). 122:2757–2762. 2009.PubMed/NCBI
27	Shiratori Y, Kawase T, Nakata R, Tanaka M, Hikiba Y, Okano K, Matsumura M, Niwa Y, Komatsu Y, Shiina S, et al: Effect of splenectomy on hepatic metastasis of colon carcinoma and natural killer activity in the liver. Dig Dis Sci. 40:2398–2406. 1995. View Article : Google Scholar : PubMed/NCBI
28	Higashijima J, Shimada M, Chikakiyo M, Miyatani T, Yoshikawa K, Nishioka M, Iwata T and Kurita N: Effect of splenectomy on antitumor immune system in mice. Anticancer Res. 29:385–393. 2009.PubMed/NCBI
29	Sonoda K, Izumi K, Matsui Y, Inomata M, Shiraishi N and Kitano S: Decreased growth rate of lung metastatic lesions after splenectomy in mice. Eur Surg Res. 38:469–475. 2006. View Article : Google Scholar : PubMed/NCBI
30	Wayman J, Bennett MK, Raimes SA and Griffin SM: The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction. Br J Cancer. 86:1223–1229. 2002. View Article : Google Scholar : PubMed/NCBI
31	Yamashita H, Katai H, Morita S, Saka M, Taniguchi H and Fukagawa T: Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg. 254:274–280. 2011. View Article : Google Scholar : PubMed/NCBI
32	Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, et al: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. J Clin Oncol. 30:268–273. 2012. View Article : Google Scholar : PubMed/NCBI
33	Takahashi H, Arimura Y, Yamashita K, Okahara S, Tanuma T, Kodaira J, Hokari K, Tsukagoshi H, Shinomura Y and Hosokawa M: Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol. 5:122–128. 2010. View Article : Google Scholar : PubMed/NCBI
34	Yamasaki M, Miyata H, Tanaka K, Shiraishi O, Motoori M, Peng YF, Yasuda T, Yano M, Shiozaki H, Mori M, et al: Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology. 80:307–313. 2011. View Article : Google Scholar : PubMed/NCBI
35	Ui T, Fujii H, Hosoya Y, Nagase M, Mieno MN, Mori M, Zuiki T, Saito S, Kurashina K, Haruta H, et al: Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus. Dis Esophagus. 28:180–187. 2015. View Article : Google Scholar : PubMed/NCBI
36	Korst RJ, Kansler AL, Port JL, Lee PC, Kerem Y and Altorki NK: Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma. Ann Thorac Surg. 82:480–485. 2006. View Article : Google Scholar : PubMed/NCBI
37	Noble F, Nolan L, Bateman AC, Byrne JP, Kelly JJ, Bailey IS, Sharland DM, Rees CN, Iveson TJ, Underwood TJ, et al: Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J Gastroenterol. 19:9282–9293. 2013. View Article : Google Scholar : PubMed/NCBI